ITGAM and leukemia: Emodin did not affect the level of CD3 surface marker (Figure 8(a)); however, emodin increased the levels of CD19 (Figure 8(b)) and CD11b (Figure 8(c)) in emodin-treated groups and it also decreased the level of Mac-3 marker after emodin at 5 and 10 mg/kg treatment (Figure 8(d)) in comparison to leukemia mice group.